Antoinette Paone Sells 6,719 Shares of Generation Bio Co. (NASDAQ:GBIO) Stock

Generation Bio Co. (NASDAQ:GBIO) COO Antoinette Paone sold 6,719 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $2.74, for a total transaction of $18,410.06. Following the completion of the sale, the chief operating officer now owns 13,807 shares of the company’s stock, valued at $37,831.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Generation Bio Trading Up 4.3 %

NASDAQ:GBIO opened at $2.44 on Friday. Generation Bio Co. has a 12 month low of $0.86 and a 12 month high of $6.98. The firm has a fifty day simple moving average of $3.05 and a 200-day simple moving average of $2.72.

Generation Bio (NASDAQ:GBIO) last posted its earnings results on Monday, May 13th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.76). The business had revenue of $4.06 million for the quarter, compared to analyst estimates of $3.02 million. Generation Bio had a negative net margin of 1,696.87% and a negative return on equity of 82.33%. On average, sell-side analysts predict that Generation Bio Co. will post -1.68 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GBIO. PFG Advisors purchased a new position in Generation Bio in the first quarter valued at $41,000. Artal Group S.A. increased its holdings in Generation Bio by 0.6% in the first quarter. Artal Group S.A. now owns 2,830,591 shares of the company’s stock valued at $11,521,000 after buying an additional 16,400 shares in the last quarter. Vanguard Group Inc. increased its holdings in Generation Bio by 0.7% in the first quarter. Vanguard Group Inc. now owns 2,570,456 shares of the company’s stock valued at $10,462,000 after buying an additional 18,205 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in Generation Bio in the first quarter valued at $74,000. Finally, Panagora Asset Management Inc. purchased a new position in Generation Bio in the fourth quarter valued at $49,000. 95.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GBIO has been the subject of several recent analyst reports. Wedbush restated an “outperform” rating and issued a $5.00 target price on shares of Generation Bio in a research note on Tuesday, May 14th. Needham & Company LLC restated a “buy” rating and issued a $10.00 target price on shares of Generation Bio in a research note on Tuesday, May 14th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $8.00.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.